DLX 7
Alternative Names: DLX-007; DLX-7; TBGLatest Information Update: 20 Feb 2023
At a glance
- Originator Delix Therapeutics
- Class Antidepressants; Azepines; Indoles; Neuropsychotherapeutics; Small molecules
- Mechanism of Action Serotonin 5-HT2A receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical CNS disorders
Most Recent Events
- 14 Feb 2023 Delix Therapeutics plans a phase I clinical trial for CNS disorders, in the first half of 2023
- 07 Dec 2021 Delix Therapeutics and National Institute on Drug Abuse agree to evaluate DLX 7 for substance related disorders
- 28 Apr 2021 Preclinical trials in CNS disorders in USA (unspecified route)